期刊
CYTOTHERAPY
卷 13, 期 7, 页码 774-785出版社
ELSEVIER SCI LTD
DOI: 10.3109/14653249.2011.553593
关键词
cancer immunotherapy; cell fusion; dendritic cells; fusogenic membrane glycoproteins
类别
资金
- Burgundy committee of the French National League against Cancer
- Saone-et-Loire committee of the French National League against Cancer
- French Association for Cancer Research (ARC)
Dendritic cells (DC) are professional antigen-presenting cells currently being used as a cellular adjuvant in cancer immunotherapy strategies. Unfortunately, DC-based vaccines have not demonstrated spectacular clinical results. DC loading with tumor antigens and DC differentiation and activation still require optimization. An alternative technique for providing antigens to DC consists of the direct fusion of dendritic cells with tumor cells. These resulting hybrid cells may express both major histocompatibility complex (MHC) class I and II molecules associated with tumor antigens and the appropriate co-stimulatory molecules required for T-cell activation. Initially tested in animal models, this approach has now been evaluated in clinical trials, although with limited success. We summarize and discuss the results from the animal studies and first clinical trials. We also present a new approach to inducing hybrid formation by expression of viral fusogenic membrane glycoproteins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据